LiSTa Therapeutics Agrees to Be Acquired by Kuva Labs in $4/Share Cash Deal

LiSTa Therapeutics Inc. (NASDAQ: LSTA) agreed to be acquired by Kuva Labs Inc. in a cash transaction valued at $4 per share, according to a press release issued on January 21, 2026. The deal, which values LiSTa at approximately $380 million based on its fully diluted shares outstanding, is expected to close in the first quarter of 2026, subject to regulatory approvals and customary closing conditions. Under the terms, LiSTa shareholders will receive $4 in cash for each share held, representing a 45% premium to the company’s 30-day volume-weighted average price as of January 20, 2026. Kuva Labs, a clinical-stage biopharmaceutical company focused on rare disease therapies, aims to expand its pipeline through the integration of LiSTa’s investigational gene therapy programs. The acquisition aligns with Kuva’s strategy to accelerate development of next-generation treatments for inherited metabolic disorders.